Early detection is the key to fighting pancreatic cancer. Our Cancer of the Pancreas Screening Study (CAPS 3) will screen individuals for pancreatic cancer and its precursors using state-of-the-art imaging tests (CT scan, MRI/MRCP, and endoscopic ultrasound) and a panel of biomarkers. This study is the first national American study of its kind, currently involving 5 sites – Johns Hopkins Hospital (Baltimore, Maryland), The Mayo Clinic (Rochester, Minnesota), MD Anderson Cancer Center (Houston, Texas), University of California (Los Angeles, California) and Dana-Farber Cancer Institute (Boston, Massachusetts). It will help us determine which screening test is the best, which individuals are likely to benefit most from screening, and what biomarkers in pancreatic juice and blood may be helpful in diagnosing early, curable pancreatic cancer or its precursors.

We are interested in finding participants in the following categories:

  1. Diagnosed Peutz-Jeghers syndrome (participant age 30-80)
  2. Verified BRCA2 or FAMMM/p16 gene mutation (participant age 40-80)with either at least one blood relative (parent, child, sibling, aunt, uncle, grandparent, first cousin) with pancreatic cancer
  3. Verified family history of pancreatic cancer involving: 2 first degree relatives (FDR) (sibling, parent, child), or if 3 relatives at least 1 must be a FDR and the others a cousin or grandparent on the same family side. (participant age 40-80)

Interested participants should not have pancreatic cancer, or suspicious symptoms. They should also have not had screening with a pancreas-specific imaging test such as CT scan, MRI, or endoscopic ultrasound performed in the past three years.

This study will cover the cost of a genetic counseling session, blood tests for screening, and pancreatic screening using MRI, CT and endoscopic ultrasound.

Thank you for your interest in the study.

The Cancer of the Pancreas Screening (CAPS) Study Team.